Anzeige
Mehr »
Login
Donnerstag, 31.10.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
291 Leser
Artikel bewerten:
(1)

Seed Group; Dante Genomics: Seed Group joins forces with New York-based biotechnology firm Dante Genomics to accelerate science for people in the MENA region

DUBAI, UAE and NEW YORK, June 20, 2023 /PRNewswire/ -- With the aim of bringing the best of scientific solutions in healthcare to the MENA region, Seed Group, a company of the Private Office of Sheikh Saeed Bin Ahmed Al Maktoum, has announced a strategic partnership with New York-based biotechnology company Dante Genomics.

From left to right: Andrea Riposati, Co-Founder and CEO of Dante Genomics; Hisham Al Gurg, CEO of Seed Group and the Private Office of Sheikh Saeed bin Ahmed Al Maktoum

Dante Genomics is a leading global genomics and precision medicine company working to deliver better healthcare and save lives with a more human approach to health. The company works with customers across 97 countries and has created customised genomic analysis processes that have an impact on people's lives. As a strategic partner of Seed Group, Dante Genomics seeks to bring its technology and innovations to people in the MENA region with the aim of accelerating science.

Together, Seed Group and Dante Genomics will help revolutionise the healthcare sector in the region by offering products and services designed to help people make informed decisions about their health and future.

Per this partnership, Seed Group will help and guide Dante Genomics to bring its solutions to the UAE and the region. Seed Group will assist Dante Genomics growth with guidance on how to reach the

right audience, access top decision-makers in the government as well as the private sector, and contribute to adding the latest technological innovations in the region.

Hisham Al Gurg, CEO of Seed Group and the Private Office of Sheikh Saeed bin Ahmed Al Maktoum, said, "Genetics and genome sequencing are the future of healthcare. The profound impact of personalised medicine, driven by advancements in genomics, has the potential to revolutionise healthcare outcomes. In this regard, the UAE stands as an ideal hub for such industries. With its visionary leadership, cutting-edge infrastructure, and commitment to innovation, the UAE provides fertile ground for healthcare transformation."

He added, "We are thrilled to welcome Dante Genomics as our strategic partner, as their expertise in genome sequencing aligns perfectly with our mission. This partnership holds immense potential to drive forward the frontiers of healthcare, propelling the UAE as a global leader in genomics and personalised medicine."

"Dubai continues to emerge as a leading area for investing in precision medicine," said Andrea Riposati, co-founder and CEO of Dante Genomics. "Dante's clinical sequencing centre in Dubai serves as a hub for global markets, delivering best-in-class precision medicine, and we are thrilled to partner with the visionaries at Seed Group in the effort to deliver these genomic solutions."

Dante Genomics leverages genome sequencing technology and interpretation using proprietary genomic platforms based on artificial intelligence and machine learning capable of integrating and optimising all resources and information, creating important synergies for all stakeholders.

The company also collaborates with international associations and advocacy groups to find solutions to improve the quality of life of patients. In 2019, the two founders of the company won the EY award for "Best Entrepreneurs of the Year," and the company took sixth place in the list of 2023 growth leaders compiled by Statista and Il Sole 24 Ore.

Seed Group is a notable force in the technology, healthcare, hospitality, and telecommunications landscapes in the Middle East. Over the past 16 years, it has formed successful strategic alliances with leading global companies representing diverse regions to accelerate sustainable market entry and presence within the Gulf Cooperation Council countries.

About Dante Genomics

Dante Genomics is a global genomic information company building and commercialising a new class of transformative health and longevity applications based on whole genome sequencing and software. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics, and personalised medicine. The Company's assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale, and proprietary processes that enable an industrial approach to genomic sequencing. For more information, visit www.dantegenomics.com.

About Seed Group

For over 20 years, Seed Group has formed strategic alliances with leading global companies representing diverse regions and industries. These companies have propelled their business interests and goals in the Middle East and North Africa region through the support and strong base of regional connections of the Seed Group. The Group's goal is to create mutually beneficial partnerships with multinational organisations and to accelerate their sustainable market entry and presence within the MENA region. Seed Group has been a key point in the success of all its partners in the region, helping them reach their target customers and accelerate their businesses. The Private Office was established by Sheikh Saeed bin Ahmed Al Maktoum to directly invest in or assist potential business opportunities in the region, which meet The Private Office's criteria. For more information, visit www.seedgroup.com.

Dante Genomics Media Contact
Laura D'Angelo
+39 0862 191 0671
ir@dantelabs.com

Seed Group Media Contact
Nomarie Jean Lacsamana
+971 4 373 5068
jean@seedgroup.com

Photo - https://mma.prnewswire.com/media/2105446/Dante_Genomics_and_Seed_Group.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/seed-group-joins-forces-with-new-york-based-biotechnology-firm-dante-genomics-to-accelerate-science-for-people-in-the-mena-region-301854519.html

© 2023 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.